Veracyte
VCYT
43.16
-1.49
-3.34%
Veracyte
US · VCYT
#2330 by market cap
Listed 1970
43.16
-1.49
-3.34%
Live - 5344 symbols - heartbeat 205s ago
· 2026-10-08 08:04
Pre-market
42.70
-1.07%
After-hours
43.16
0.00%
Overnight
43.00
-0.37%
- Market cap
- 3.47B
- P/E (TTM)i
- 30.83
- P/Bi
- 2.50
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on VCYT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 22.13, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.01% YoY
Margins
- Gross margin
- 70.10%
- Operating margin
- 15.14%
- Net margin
- 12.83%
Key ratios & quality
- Altman Z-Scorei
- 22.13
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 92.01M | 120.37M | 117.48M | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Gross profit | 58.93M | 83.85M | 76.03M | 145.11M | 175.68M | 229.68M | 298.15M | 362.53M |
| Selling & admin expenses | 65.28M | 82.72M | 89.12M | 181.19M | 170.76M | 187.72M | 206.04M | 210.95M |
| Research & development | 14.82M | 14.85M | 17.20M | 29.84M | 40.60M | 57.31M | 69.29M | 70.81M |
| Operating profit | -22.23M | -15.13M | -35.39M | -80.37M | -35.34M | -17.45M | 19.51M | 78.28M |
| Pretax profit | -23.00M | -12.60M | -34.91M | -81.65M | -36.43M | -76.61M | 25.74M | 68.20M |
| Tax | -- | 0 | 0 | -6.09M | 133.00K | -2.21M | 1.61M | 1.85M |
| Net profit | -23.00M | -12.60M | -34.91M | -75.56M | -36.56M | -74.40M | 24.14M | 66.35M |
| Basic EPS | -1 | 0 | -1 | -1 | -1 | -1 | 0 | 1 |
| Diluted EPS | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 114.47M | 130.16M | 131.87M | 140.64M | 139.07M | 150.32M |
| Gross profit | 79.51M | 89.77M | 91.28M | 101.97M | 101.16M | 108.55M |
| Selling & admin expenses | 58.26M | 57.65M | 50.71M | 43.47M | 50.84M | 55.71M |
| Research & development | 17.72M | 16.26M | 15.98M | 20.85M | 27.10M | 29.44M |
| Operating profit | 2.90M | 15.24M | 23.11M | 39.91M | 22.65M | 22.98M |
| Pretax profit | 7.43M | 1.25M | 18.89M | 40.63M | 29.97M | 26.52M |
| Tax | 381.00K | 2.23M | -248.00K | -515.00K | 1.27M | 1.03M |
| Net profit | 7.05M | -980.00K | 19.14M | 41.15M | 28.71M | 25.49M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | 0 |
| Diluted EPS | 0.09 | -0.01 | 0.24 | 0.51 | 0.35 | 0.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 96.95M | 187.69M | 375.68M | 243.10M | 248.64M | 285.62M | 372.27M | 488.38M |
| Cash & ST investments | 78.00M | 159.32M | 349.36M | 177.16M | 178.85M | 216.45M | 289.44M | 412.89M |
| Inventory | 3.40M | 6.81M | 4.66M | 11.23M | 14.29M | 16.13M | 21.75M | 20.55M |
| Total assets | 120.64M | 275.21M | 457.16M | 1.19B | 1.16B | 1.11B | 1.30B | 1.41B |
| Total current liabilities | 13.06M | 17.47M | 16.78M | 64.15M | 62.61M | 61.24M | 78.63M | 59.94M |
| Short-term debt | 1.36M | 1.41M | 1.59M | 4.76M | 4.07M | 5.11M | 7.50M | 4.05M |
| Long-term debt | 23.93M | 694.00K | 810.00K | -- | -- | -- | -- | -- |
| Total liabilities | 40,883,000.00 | 35,757,000.00 | 35,931,000.00 | 91,311,000.00 | 81,222,000.00 | 70,804,000.00 | 124,069,000.00 | 96,443,000.00 |
| Total equity | 79.76M | 239.46M | 421.23M | 1.10B | 1.08B | 1.04B | 1.18B | 1.31B |
| Retained earnings | -234.09M | -246.69M | -281.59M | -357.16M | -393.72M | -468.12M | -443.98M | -377.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 383.15M | 414.68M | 449.22M | 488.38M | 522.18M | 574.78M |
| Cash & ST investments | 287.36M | 320.72M | 366.43M | 412.89M | 439.06M | 485.23M |
| Inventory | 24.25M | 25.02M | 20.33M | 20.55M | 21.42M | 22.66M |
| Total assets | 1.32B | 1.34B | 1.37B | 1.41B | 1.44B | 1.49B |
| Total current liabilities | 75.13M | 76.43M | 72.15M | 59.94M | 56.12M | 62.74M |
| Short-term debt | 7.41M | 6.41M | 4.28M | 4.05M | 4.35M | 5.78M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 120,475,000.00 | 123,047,000.00 | 110,120,000.00 | 96,443,000.00 | 91,994,000.00 | 97,963,000.00 |
| Total equity | 1.19B | 1.22B | 1.26B | 1.31B | 1.34B | 1.39B |
| Retained earnings | -436.94M | -437.92M | -418.78M | -377.63M | -348.92M | -323.43M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.52M | -3.23M | -9.71M | -31.62M | 7.54M | 44.22M | 75.10M | 136.31M |
| Depreciation & amortization | 3.92M | 4.12M | 7.94M | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| Free cash flow | -15.40M | -5.99M | -12.55M | -37.00M | -1.01M | 34.26M | 63.81M | 126.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 55.04M | 137.85M | 193.83M | 593.82M | -- | -- | -- | -- |
| Ending cash balance | 78.60M | 159.92M | 349.97M | 173.95M | 155.00M | 217.33M | 240.63M | 364.23M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 5.36M | 33.61M | 44.76M | 52.58M | 35.22M | 45.83M |
| Depreciation & amortization | 5.36M | 5.49M | 5.27M | 5.30M | 5.43M | 4.84M |
| Free cash flow | 3.54M | 32.32M | 41.97M | 48.80M | 32.25M | 42.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 187.77M | 221.15M | 317.21M | 364.23M | 264.79M | 301.19M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -39.32 | -7.89 | -10.57 | -9.96 | -3.37 | -7.02 | 2.17 | 5.34 |
| ROA %i | -23.08 | -6.37 | -9.53 | -9.19 | -3.12 | -6.55 | 2.00 | 4.90 |
| ROIC %i | -24.91 | -6.66 | -10.10 | -9.74 | -3.44 | -7.60 | 1.20 | 4.19 |
| 5-year avg ROE %i | -58.56 | -48.13 | -35.68 | -26.36 | -14.22 | -7.76 | -5.75 | -2.57 |
| EBIT margin %i | -22.86 | -9.90 | -29.52 | -37.09 | -12.22 | -21.22 | 5.78 | 13.19 |
| FCF / sales %i | -- | -- | -- | -- | -- | 9.49 | 14.31 | 24.49 |
| Current ratioi | 7.42 | 10.74 | 22.39 | 3.79 | 3.97 | 4.66 | 4.73 | 8.15 |
| Quick ratioi | 6.98 | 10.23 | 21.92 | 3.41 | 3.56 | 4.19 | 4.27 | 7.63 |
| Debt / assetsi | 20.96 | 4.94 | 2.69 | 1.59 | 1.27 | 1.13 | 3.90 | 2.82 |
| LT debt / equityi | 30.00 | 5.09 | 2.55 | 1.29 | 0.99 | 0.72 | 3.68 | 2.72 |
| Interest coveragei | -10.72 | -17.61 | -151.44 | -337.79 | -182.97 | -5,106.47 | 12,873.00 | 68,202.00 |
| Revenue CAGR (3Y) %i | 22.95 | 22.75 | 17.75 | 33.62 | 35.06 | 45.39 | 26.63 | 20.37 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 2.86 | 2.24 | 2.49 | 5.34 | 6.93 | 8.77 |
| ROA %i | 2.63 | 2.04 | 2.29 | 4.90 | 6.40 | 8.09 |
| ROIC %i | 1.89 | 1.31 | 1.49 | 4.19 | 5.70 | 7.43 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.60 | 6.05 | 6.26 | 13.19 | 16.75 | 20.65 |
| FCF / sales %i | 16.93 | 17.52 | 19.83 | 24.49 | 28.67 | 29.54 |
| Current ratioi | 5.10 | 5.43 | 6.23 | 8.15 | 9.31 | 9.16 |
| Quick ratioi | 4.54 | 4.86 | 5.74 | 7.63 | 8.72 | 8.60 |
| Debt / assetsi | 3.84 | 3.77 | 2.96 | 2.82 | 2.74 | 2.70 |
| LT debt / equityi | 3.61 | 3.62 | 2.88 | 2.72 | 2.60 | 2.47 |
| Interest coveragei | -- | 14,485.50 | 31,011.00 | 68,202.00 | 90,748.00 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of diagnostic tests and biopharmaceutical services100.00%
Quote time 2026-10-08 08:04:59 · For reference only, not investment advice and not tailored to your situation.